MiMedx Group Inc - Asset Resilience Ratio
MiMedx Group Inc (MDXG) has an Asset Resilience Ratio of -35.74% as of March 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2016)
This chart shows how MiMedx Group Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of MiMedx Group Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down MiMedx Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MiMedx Group Inc (MDXG) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $-43.90 Million | -35.74% |
| Total Liquid Assets | $-43.90 Million | -35.74% |
Asset Resilience Insights
- Limited Liquidity: MiMedx Group Inc maintains only -35.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
MiMedx Group Inc Industry Peers by Asset Resilience Ratio
Compare MiMedx Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for MiMedx Group Inc (2011–2016)
The table below shows the annual Asset Resilience Ratio data for MiMedx Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.00% | $0.00 | $193.26 Million | -- |
| 2015-12-31 | 2.21% | $3.00 Million | $135.91 Million | -3.06pp |
| 2014-12-31 | 5.26% | $5.75 Million | $109.26 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $84.69 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $35.18 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $27.10 Million | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more